Immunovirological outcome and HIV-1 DNA decay in a small cohort of HIV-1-infected patients deintensificated from Abacavir/Lamivudine/Dolutegravir to Lamivudine plus Dolutegravir

Massimiliano Lanzafame, Stefano Nicole, Sebastiano Rizzardo, Daniela Piacentini, Sheila Chiesi, Emanuela Lattuada, Erica Diani, Maria Carelli, Sandro Vento, Davide Gibellini

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Combination abacavir/lamivudine/dolutegravir (ABC/3TC/DTG) is approved as a first-line treatment for antiretroviral naïve patients. This report investigated the immunovirological outcome and total HIV-1 DNA decay in a small cohort of naïve HIV-1-positive patients treated with this regimen. In the presence of viral suppression and increased lymphocyte T CD4+ cells, the quantitative analysis of total HIV-1 DNA content revealed a significant decay after 12 months of treatment. Subsequently, we deintensificated the treatment of these patients from (ABC/3TC/DTG) to lamivudine plus dolutegravir (3TC/DTG) after 12 months of virological suppression, as a strategy of "induction-maintenance" therapy. The analysis of HIV-1 RNA viral load, total HIV-1 DNA, CD4+ T lymphocyte count and CD8+ HLA-DR+ T lymphocyte percentage after a mean 3.5 months of therapy deintensification showed no significant difference with respect to data detected after 12 months of ABC/3TC/DTG treatment in the presence of continuous viral suppression. These results indicate that the deintensification of highly active antiretroviral therapy (HAART) from ABC/ 3TC/DTG to 3TC/DTG effectively controls HIV-1 replication and in the early period does not induce any significant variations of total HIV-1 DNA. This suggests that HAART deintensification might be proposed as a therapeutic evolution in the treatment of HIV-1 infection.

Original languageEnglish
Pages (from-to)262-267
Number of pages6
JournalThe new microbiologica
Volume41
Issue number4
Publication statusPublished - Oct 1 2018

Fingerprint

Lamivudine
HIV-1
DNA
Highly Active Antiretroviral Therapy
Therapeutics
T-Lymphocytes
lamivudine drug combination abacavir
dolutegravir
HLA-DR Antigens
CD4 Lymphocyte Count
Viral Load
HIV Infections
Maintenance
Lymphocytes
RNA

Keywords

  • Abacavir/lamivudine/dolutegravir
  • Deintensification
  • HAART
  • HIV DNA decay

ASJC Scopus subject areas

  • Microbiology (medical)

Cite this

Immunovirological outcome and HIV-1 DNA decay in a small cohort of HIV-1-infected patients deintensificated from Abacavir/Lamivudine/Dolutegravir to Lamivudine plus Dolutegravir. / Lanzafame, Massimiliano; Nicole, Stefano; Rizzardo, Sebastiano; Piacentini, Daniela; Chiesi, Sheila; Lattuada, Emanuela; Diani, Erica; Carelli, Maria; Vento, Sandro; Gibellini, Davide.

In: The new microbiologica, Vol. 41, No. 4, 01.10.2018, p. 262-267.

Research output: Contribution to journalArticle

Lanzafame, M, Nicole, S, Rizzardo, S, Piacentini, D, Chiesi, S, Lattuada, E, Diani, E, Carelli, M, Vento, S & Gibellini, D 2018, 'Immunovirological outcome and HIV-1 DNA decay in a small cohort of HIV-1-infected patients deintensificated from Abacavir/Lamivudine/Dolutegravir to Lamivudine plus Dolutegravir', The new microbiologica, vol. 41, no. 4, pp. 262-267.
Lanzafame, Massimiliano ; Nicole, Stefano ; Rizzardo, Sebastiano ; Piacentini, Daniela ; Chiesi, Sheila ; Lattuada, Emanuela ; Diani, Erica ; Carelli, Maria ; Vento, Sandro ; Gibellini, Davide. / Immunovirological outcome and HIV-1 DNA decay in a small cohort of HIV-1-infected patients deintensificated from Abacavir/Lamivudine/Dolutegravir to Lamivudine plus Dolutegravir. In: The new microbiologica. 2018 ; Vol. 41, No. 4. pp. 262-267.
@article{dd4540d7bfec4d899759c8a3d376935b,
title = "Immunovirological outcome and HIV-1 DNA decay in a small cohort of HIV-1-infected patients deintensificated from Abacavir/Lamivudine/Dolutegravir to Lamivudine plus Dolutegravir",
abstract = "Combination abacavir/lamivudine/dolutegravir (ABC/3TC/DTG) is approved as a first-line treatment for antiretroviral na{\"i}ve patients. This report investigated the immunovirological outcome and total HIV-1 DNA decay in a small cohort of na{\"i}ve HIV-1-positive patients treated with this regimen. In the presence of viral suppression and increased lymphocyte T CD4+ cells, the quantitative analysis of total HIV-1 DNA content revealed a significant decay after 12 months of treatment. Subsequently, we deintensificated the treatment of these patients from (ABC/3TC/DTG) to lamivudine plus dolutegravir (3TC/DTG) after 12 months of virological suppression, as a strategy of {"}induction-maintenance{"} therapy. The analysis of HIV-1 RNA viral load, total HIV-1 DNA, CD4+ T lymphocyte count and CD8+ HLA-DR+ T lymphocyte percentage after a mean 3.5 months of therapy deintensification showed no significant difference with respect to data detected after 12 months of ABC/3TC/DTG treatment in the presence of continuous viral suppression. These results indicate that the deintensification of highly active antiretroviral therapy (HAART) from ABC/ 3TC/DTG to 3TC/DTG effectively controls HIV-1 replication and in the early period does not induce any significant variations of total HIV-1 DNA. This suggests that HAART deintensification might be proposed as a therapeutic evolution in the treatment of HIV-1 infection.",
keywords = "Abacavir/lamivudine/dolutegravir, Deintensification, HAART, HIV DNA decay",
author = "Massimiliano Lanzafame and Stefano Nicole and Sebastiano Rizzardo and Daniela Piacentini and Sheila Chiesi and Emanuela Lattuada and Erica Diani and Maria Carelli and Sandro Vento and Davide Gibellini",
year = "2018",
month = "10",
day = "1",
language = "English",
volume = "41",
pages = "262--267",
journal = "New Microbiologica",
issn = "1121-7138",
publisher = "Luigi Ponzio e figlio Editori",
number = "4",

}

TY - JOUR

T1 - Immunovirological outcome and HIV-1 DNA decay in a small cohort of HIV-1-infected patients deintensificated from Abacavir/Lamivudine/Dolutegravir to Lamivudine plus Dolutegravir

AU - Lanzafame, Massimiliano

AU - Nicole, Stefano

AU - Rizzardo, Sebastiano

AU - Piacentini, Daniela

AU - Chiesi, Sheila

AU - Lattuada, Emanuela

AU - Diani, Erica

AU - Carelli, Maria

AU - Vento, Sandro

AU - Gibellini, Davide

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Combination abacavir/lamivudine/dolutegravir (ABC/3TC/DTG) is approved as a first-line treatment for antiretroviral naïve patients. This report investigated the immunovirological outcome and total HIV-1 DNA decay in a small cohort of naïve HIV-1-positive patients treated with this regimen. In the presence of viral suppression and increased lymphocyte T CD4+ cells, the quantitative analysis of total HIV-1 DNA content revealed a significant decay after 12 months of treatment. Subsequently, we deintensificated the treatment of these patients from (ABC/3TC/DTG) to lamivudine plus dolutegravir (3TC/DTG) after 12 months of virological suppression, as a strategy of "induction-maintenance" therapy. The analysis of HIV-1 RNA viral load, total HIV-1 DNA, CD4+ T lymphocyte count and CD8+ HLA-DR+ T lymphocyte percentage after a mean 3.5 months of therapy deintensification showed no significant difference with respect to data detected after 12 months of ABC/3TC/DTG treatment in the presence of continuous viral suppression. These results indicate that the deintensification of highly active antiretroviral therapy (HAART) from ABC/ 3TC/DTG to 3TC/DTG effectively controls HIV-1 replication and in the early period does not induce any significant variations of total HIV-1 DNA. This suggests that HAART deintensification might be proposed as a therapeutic evolution in the treatment of HIV-1 infection.

AB - Combination abacavir/lamivudine/dolutegravir (ABC/3TC/DTG) is approved as a first-line treatment for antiretroviral naïve patients. This report investigated the immunovirological outcome and total HIV-1 DNA decay in a small cohort of naïve HIV-1-positive patients treated with this regimen. In the presence of viral suppression and increased lymphocyte T CD4+ cells, the quantitative analysis of total HIV-1 DNA content revealed a significant decay after 12 months of treatment. Subsequently, we deintensificated the treatment of these patients from (ABC/3TC/DTG) to lamivudine plus dolutegravir (3TC/DTG) after 12 months of virological suppression, as a strategy of "induction-maintenance" therapy. The analysis of HIV-1 RNA viral load, total HIV-1 DNA, CD4+ T lymphocyte count and CD8+ HLA-DR+ T lymphocyte percentage after a mean 3.5 months of therapy deintensification showed no significant difference with respect to data detected after 12 months of ABC/3TC/DTG treatment in the presence of continuous viral suppression. These results indicate that the deintensification of highly active antiretroviral therapy (HAART) from ABC/ 3TC/DTG to 3TC/DTG effectively controls HIV-1 replication and in the early period does not induce any significant variations of total HIV-1 DNA. This suggests that HAART deintensification might be proposed as a therapeutic evolution in the treatment of HIV-1 infection.

KW - Abacavir/lamivudine/dolutegravir

KW - Deintensification

KW - HAART

KW - HIV DNA decay

UR - http://www.scopus.com/inward/record.url?scp=85059494120&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059494120&partnerID=8YFLogxK

M3 - Article

C2 - 30311623

AN - SCOPUS:85059494120

VL - 41

SP - 262

EP - 267

JO - New Microbiologica

JF - New Microbiologica

SN - 1121-7138

IS - 4

ER -